Genome-wide association study of copy number variations in Parkinson’s disease

Competing Interest Statement

A.B. Singleton reports grants from the Department of Defense during the conduct of the study and grants from The Michael J. Fox Foundation outside the submitted work. A.B.Singleton is an unpaid Scientific Advisory Board member for Cajal Neuroscience outside of the submitted work W.P. reports personal fees from Grunenthal, AbbVie, AOP Orphan, and Zambon; personal fees and others from Boehringer Ingelheim; and personal fees from Stada and UCB Pharma outside the submitted work. A.E. Lang reports personal fees from AbbVie, AFFiRis, Janssen, Biogen, Merck, Sun Pharma, Corticobasal Solutions, Sunovion, Paladin, Lilly, Medtronic, Theravance, Lundbeck, Retrophin, Roche, and PhotoPharmics outside the submitted work. A. Brice reports grants from France Parkinson + FRC, ANR-EPIG-Agence nationale de recherche, ANR, JPND, Agence nationale de recherche, RDS (Roger de Spoelberch Foundation), France Alzheimer, Institut de France, ANR EPIG, and FMR (maladies rares) outside the submitted work. J.-C. Corvol reports grants from The Michael J. Fox Foundation and Sanofi and served on the advisory boards of Air Liquide, Biogen, Denali, Ever Pharma, Idorsia, Prevail Therapeutic, Theranexus, and UCB outside the submitted work. M.-C. Chartier-Harlin reports grants from France Parkinson, ANR Agence nationale de recherche (MetDePaDi, Synapark), and ANR JPND (TransNeuro), Agence nationale de recherche, Grant; Fondation de France, and The Michael J. Fox Foundation outside the submitted work. K. Brockmann has received research funding from the Michael J. Fox Foundation for Parkinson's Research (MJFF-022343, MJFF-023275, MJFF-023365), the German Society for Parkinson DPG, the Health Forum Baden Wuerttemberg, the Else Kroner Fresenius Stiftung (ClinbrAIn), the University of Tuebingen, and from the German Research Foundation DFG (BR-655671-1. KB is a consultant for F. Hoffmann-La Roche Ltd., Vanqua Bio, and the Michael J. Fox Foundation for Parkinson's Research and has received speaker honoraria from Abbvie, Lundbeck, UCB and Zambon. L. Stefanis reports the following grants: PPMI2 (supported by The Michael J. Fox Foundation), IMPRIND-IMI2 number 116060 (EU, H2020), Transferring Autonomous and Non-Autonomous Cell Degeneration 3D Models between EU and USA for Development of Effective Therapies for Neurodegenerative Diseases (ND) - CROSS NEUROD (H2020-EU 1.3.3., grant number778003); Chaperone-Mediated Autophagy in Neurodegeneration (Hellenic Foundation for Research and Innovation Grant HFRI-FM17-3013); and CMA as a Means to Counteract alpha-Synuclein Pathology in Non-Human Primates Grant by The Michael J. Fox Foundation (collaborator). He is co-head and Principal Investigator at the NKUA of the General Secretariat of Research and Technology (GSRT)-funded Grant National Network of Precision Medicine for Neurodegenerative Diseases. He has served on the advisory boards of AbbVie, ITF Hellas, and Biogen and has received honoraria from AbbVie and Sanofi. There are no specific disclosures related to the current work. E.M. Valente serves as associate editor of the Journal of Medical Genetics, section editor of Pediatric Research, and member of the editorial board of Movement Disorders Clinical Practice and received grants from the Italian Ministry of Health, CARIPLO Foundation, Pierfranco and Luisa Mariani Foundation, and Telethon Foundation Italy outside the submitted work. N. Hattori reports grants from the Japan Agency for Medical Research and Development (AMED), the Japan Society for the Promotion of Science (JSPS), and the Ministry of Education Culture, Sports, Science and Technology Japan; Grant-in-Aid for Scientific Research on Innovative Areas; personal fees and others from Dai-Nippon Sumitomo Pharma Co., Ltd, Takeda Pharmaceutical Co., Ltd, Kyowa Kirin Co., Ltd, GSK K.K., Nippon Boehringer Ingelheim, Co., Ltd, FP Pharmaceutical Corporation, Eisai Co., Ltd, Kissei Pharmaceutical Company, Nihon Medi-physics Co., Ltd, Novartis Pharma K.K., Biogen Idec Japan Ltd, AbbVie, and Medtronic, Inc.; others from Boston Scientific Japan; personal fees and others from Astellas Pharma Inc.; grants and others from Ono Pharmaceutical Co., Ltd; others from Nihon Pharmaceutical Co., Ltd, Asahi Kasei Medical Co., Ltd, and Mitsubishi Tanabe Pharma Corporation; personal fees and others from Daiichi Sankyo Co.; others from OHARA Pharmaceutical Co., Ltd, and Meiji Seika Pharma; personal fees from Sanofi K.K., Pfizer Japan Inc., Alexion Pharmaceuticals, Mylan N.V., MSD K.K., Lund Beck Japan; and others from Hisamitsu Pharmaceutical Co., Inc. outside the submitted work. K. Nishioka reports grants from the Japan Society for the Promotion of Science (JSPS) outside the submitted work. P. Kolber reports others from Centre Hospitalier de Luxembourg, University of Luxembourg, and grants from the Fonds National de Recherche (FNR), from null, outside the submitted work. B.P.C. van de Warrenburg reports grants from ZonMW, Hersenstichting, and uniQure; others from uniQure; and grants from Gossweiler Fund and Radboud University Medical Centre outside the submitted work. B.R. Bloem reports grants from the Netherlands Organization for Health Research and Development, The Michael J. Fox Foundation, Parkinson Vereniging, Parkinson Foundation, Gatsby Foundation, Verily Life Sciences, Horizon 2020, Topsector Life Sciences and Health, Stichting Parkinson Fonds, UCB, and AbbVie during the conduct of the study and personal fees from Biogen, AbbVie, Walk with Path, UCB, AbbVie, Zambon, Bial, and Roche outside the submitted work and serves as editor in chief of the Journal of Parkinson's Diseaseand serves on the editorial board of Practical Neurology and Digital Biomarkers. M. Toft reports grants from the Research Council of Norway during the conduct of the study and grants from the South-Eastern Norway Regional Health Authority and The Michael J. Fox Foundation outside the submitted work. L. Pihlstrom reports grants from the Norwegian Health Association and the South-Eastern Norway Regional Health Authority outside the submitted work. J.J. Ferreira reports grants from GlaxoSmithKline, Grunenthal, Fundacao MSD (Portugal), Teva, MSD, Allergan, Novartis, Medtronic, Lundbeck, Solvay, Bial, Merck-Serono, Merz, Ipsen, Biogen, Acadia, Allergan, AbbVie, and Sunovion Pharmaceuticals and personal fees from Faculdade de Medicina de Lisboa, CNS Campus Neurologico Senior, Bial, and Novartis outside the submitted work. E. Tolosa received honoraria for consultancy from Teva, Bial, Prevail Therapeutics, Boehringer Ingelheim, Roche, and Biogen and has received funding for research from the Spanish Network for Research on Neurodegenerative Disorders (CIBERNED) Instituto Carlos III (ISCIII) and The Michael J. Fox Foundation for Parkinson's Research (MJFF). A. Puschmann reports grants from Parkinsonfonden (The Swedish Parkinson Foundation), ALF (Swedish government), Region Skane, Sweden, Skane University Hospital, and Hans-Gabriel och Trolle Wachtmeister Stiftelse for Medicinsk Forskning, Sweden, Multipark a strategic research environment at Lund University during the conduct of the study and personal fees from Elsevier outside the submitted work. R. Krueger reports grants from the Fonds National de Recherche (FNR), and the German Research Council (DFG); nonfinancial support from AbbVie and Zambon during the conduct of the study; personal fees from the University of Luxembourg, Luxembourg Institute of Health, and Centre Hospitalier de Luxembourg; grants from the Fonds National de Recherche, Luxembourg (FNR), and Luxembourg/German Research Council (DFG); and personal fees from Desitin/Zambon, AbbVie GmbH, and Medtronic GmbH outside the submitted work. T. Gasser reports personal fees from UCB Pharma, Novartis, Teva, and MedUpdate; grants from The Michael J. Fox Foundation for Parkinson's Research, Bundesministerium fur Bildung und Forschung (BMBF), and Deutsche Forschungsgemeinschaft (DFG); and others from Joint Programming for Neurodegenerative Diseases (JPND) program, funded by the European Commission, outside the submitted work; in addition, Dr. Gasser has a patent, patent number: EP1802749 (A2) KASPP (LRRK2) Gene, Its production and Use for the Detection and Treatment of Neurodegenerative Disorders Issued. W. Pirker reports personal fees from Grunenthal, AbbVie, AOP Health Orphan, Zambon, Boehringer Ingelheim, Stada, Bial UCB Pharma, outside the submitted work. All the other authors reports no disclosures relevant to the manuscript

Funding Statement

This study used data from the Courage-PD consortium, conducted under a partnership agreement among 35 studies. The Courage-PD consortium is supported by the EU Joint Program for Neurodegenerative Disease research (JPND https://neurodegenerationresearch.eu). P. May was funded by the Fonds National de Recherche (FNR), Luxembourg, as part of the National Centre of Excellence in Research on Parkinsons Disease (NCER-PD, FNR11264123). Z. Landoulsi and P. May were supported by the DFG Research Unit FOR2715 (INTER/DFG/17/ 11583046), FOR2488 (INTER/DFG/19/14429377) and the National Centre for Excellence in Research on Parkinsons disease (NCER-PD). A.B. Singleton, D.G. Hernandez, and C. Edsall are funded by the Intramural Research Program of the National Institute on Aging, National Institutes of Health, Department of Health and Human Services, project ZO1 AG000949. E. Rogaeva is funded by the Canadian Consortium on Neurodegeneration in Aging. S.Koks is funded by MSWA. P. Taba is the recipient of an Estonian Research Council Grant PRG957. E.M.Valente is funded by the Italian Ministry of Health (Ricerca Corrente 2021). S. Bardien and J. Carr are supported by grants from the National Research Foundation of South Africa (grant number: 106052); the South African Medical Research Council (Self-Initiated Research Grant); and Stellenbosch University, South Africa; they also acknowledge the support of the NRF-DST Centre of Excellence for Biomedical Tuberculosis Research; South African Medical Research Council Centre for Tuberculosis Research; and Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town. P. Pastor have received funding from the Spanish Ministry of Science and Innovation (SAF2013-47939-R). K. Wirdefeldt and N.L. Pedersen are funded by the Swedish Research Council, grant numbers K2002-27X-14056-02B, 521-2010-2479, 521-2013-2488, and 2017-02175. N.L. Pedersen is funded by the National Institutes of Health, grant numbers ES10758 and AG 08724. C. Ran is funded by the Marta Lundkvist Foundation, Swedish Brain Foundation, and Karolinska Institutet Research Fund. A.C. Belin is funded by the Swedish Brain Foundation, Swedish Research Council, and Karolinska Institutet Research Funds. M. Tan is funded by the Parkinson's UK. M. Sharma was supported by grants from the German Research Council (DFG/SH 599/6-1), MSA Coalition, and The Michael J. Fox Foundation (USA Genetic Diversity in PD Program: GAP-India Grant ID: 17473). A. Elbaz reports grants from Agence nationale de recherche (ANR), The Michael J. Fox Foundation, Plan Ecophyto (French Ministry of Agriculture), and France Parkinson outside the submitted work. PG GEN sample collection was funded by the MRC and UK Medical Research Council (C.E. Clarke and K.E. Morrison). The sponsors had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit the paper for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Regional Committee for Medical and Health Research Ethics of St Olav Hospital and Norwegian University of Science and Technology, Norway, gave ethical approval for this work. The Ethics Committee of the National Research Council, Cosenza, Italy, gave ethical approval for this work. The Health research Ethics Commitee at Stellenbosch University, South Africa, gave ethical approval for this work. The Committee for the Protection of Human Subjects Ile-de-France of Pitie-Salpetriere hospital, France and of Universite Paris-Saclay, France, gave ethical approval for this work. The Committee for the Protection of Human Subjects Nord-Ouest of the university of Lille, France, gave ethical approval for this work. The University of Florida Institutional Review Board, USA, gave ethical approval for this work. The Ethics Committee for Research of the Faculty of Medicine of the University of Lisbon, Portugal, gave ethical approval for this work. The Ethics Committee of the Medical Faculty of the University of Tubingen, Germany, gave ethical approval for this work. The Ethics Committee of Humanitas Research Hospital, Italy, gave ethical approval for this work. The Ethics committee of the University Hospital of Larissa, Greece, gave ethical approval for this work. The Research Ethics Committee of the University of Tartu, Estonia, gave ethical approval for this work. The Ethic review panel of the University of Luxembourg, Luxembourg, gave ethical approval for this work. The Griffith University Human Research Ethics Committee, Australia, gave ethical approval for this work. The Research Ethics Committee of the Hospital Universitari Mutua de Terrassa, Spain, gave ethical approval for this work. The Regional Ethical Review Board in Lund, Sweden, gave ethical approval for this work. The Research Ethics Board of the University of Toronto, Canada, gave ethical approval for this work. The Ethics Committee of the Biomedical Research Foundation of the Academy of Athens, Greece, gave ethical approval for this work. The Regional Committees for Medical and Health Research Ethics of the Oslo University Hospital, Norway, gave ethical approval for this work. The ethics committee of the Hospital Clinic de Barcelona, Spain, gave ethical approval for this work. The Ethical Committee of the University of Pavia, Italy, gave ethical approval for this work. The Ethical Review Board of the Karolinska Institutet, Stockholm, Sweden, gave ethical approval for this work. The Ethics Committee of the Medical University of Vienna, Austria, gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes